The Water-Blueberry Study
|ClinicalTrials.gov Identifier: NCT00520871|
Recruitment Status : Completed
First Posted : August 27, 2007
Last Update Posted : August 27, 2007
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Disease||Drug: Blueberry juice||Phase 1 Phase 2|
Participants with at leat one elevated cardiovacsular risk factor, as defined as systolic blood pressure between 140 and 165 mmHg, diastolic blood pressure between 90 and 105 mmHg, low density lipoprotein (LDL) cholesterol ≥3.4 mmol/L, total/high density lipoprotein (HDL) cholesterol ratio >4 or smoking a minimum of 3 cigarettes daily.
Subjects were randomized to two groups, where the blueberry group were supplemented with 1 L blueberry juice per day for four weeks. The control group consumed an equal amount of water.
Clinical markers, as well as biomarkers of antioxidant status, oxidative stress status and inflammation were measured in blood samples before amd after the intervention period.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||62 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Effect of Blueberry Juice on Cardiovascular Risk Factors, and Markers of Antioxidant Status, Oxidative Stress Status and Inflammation.|
|Study Start Date :||March 2003|
|Actual Study Completion Date :||April 2004|
- Primary endpoints are cardiovascular risk factors [ Time Frame: 4 weeks ]
- Secondary endpoints are additional clinical markers, as well as biomarkers of antioxidant status, oxidative stress status and inflammation [ Time Frame: 4 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00520871
|Principal Investigator:||Rune Blomhoff, PhD||University of Oslo|
|Principal Investigator:||Serena Tonstad, MD||Ullevaal University Hospital|
|Principal Investigator:||Anette Karlsen, MSc||University of Oslo|